Bryan Harvey Bodek
Vorsitzender bei NovaBiotics Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Deborah A. O’Neil | M | 53 |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 20 Jahre |
Alan Clarke | M | 74 |
The University of Manchester Intellectual Property Ltd.
The University of Manchester Intellectual Property Ltd. Miscellaneous Commercial ServicesCommercial Services The University of Manchester Intellectual Property Ltd. (UMIP) manages intellectual property for the University of Manchester. Formed in 2004, UMIP is a limited company wholly-owned by the University and located in Manchester, UK. They operate independently of the University. The University traces their history back to 1851 and more recently to 2004 when the University formally combined with UMIST (University of Manchester Institute of Science and Technology) to create a single university. UMIP acts as a technology transfer company in the UK. They have access to proof of concept funds to develop very early stage inventions to a phase where they become propositions capable of attracting investments. They also have investment funds to develop young start-up companies, along with the skills and network necessary to draw in the larger sums of external venture capital. UMIP works with researchers, entrepreneurs, business people, professional advisers and investors to achieve their goals. | - |
Steven Cloran | M | 60 |
Aero Technics Ltd.
Aero Technics Ltd. Aerospace & DefenseElectronic Technology Aero Technics Ltd. manufactures aircraft parts. The firm offers interior, design, composite materials and kitting services to airlines. The company was founded by Steve Lindsay Cloran in 2002 and is headquartered in Worthing, the United Kingdom. | 22 Jahre |
Paul Grant Ellis | M | 67 |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 11 Jahre |
Ian Townsend | M | 69 |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 13 Jahre |
Clive Rowland | M | - |
The University of Manchester Intellectual Property Ltd.
The University of Manchester Intellectual Property Ltd. Miscellaneous Commercial ServicesCommercial Services The University of Manchester Intellectual Property Ltd. (UMIP) manages intellectual property for the University of Manchester. Formed in 2004, UMIP is a limited company wholly-owned by the University and located in Manchester, UK. They operate independently of the University. The University traces their history back to 1851 and more recently to 2004 when the University formally combined with UMIST (University of Manchester Institute of Science and Technology) to create a single university. UMIP acts as a technology transfer company in the UK. They have access to proof of concept funds to develop very early stage inventions to a phase where they become propositions capable of attracting investments. They also have investment funds to develop young start-up companies, along with the skills and network necessary to draw in the larger sums of external venture capital. UMIP works with researchers, entrepreneurs, business people, professional advisers and investors to achieve their goals. | - |
Heather White | F | - |
The University of Manchester Intellectual Property Ltd.
The University of Manchester Intellectual Property Ltd. Miscellaneous Commercial ServicesCommercial Services The University of Manchester Intellectual Property Ltd. (UMIP) manages intellectual property for the University of Manchester. Formed in 2004, UMIP is a limited company wholly-owned by the University and located in Manchester, UK. They operate independently of the University. The University traces their history back to 1851 and more recently to 2004 when the University formally combined with UMIST (University of Manchester Institute of Science and Technology) to create a single university. UMIP acts as a technology transfer company in the UK. They have access to proof of concept funds to develop very early stage inventions to a phase where they become propositions capable of attracting investments. They also have investment funds to develop young start-up companies, along with the skills and network necessary to draw in the larger sums of external venture capital. UMIP works with researchers, entrepreneurs, business people, professional advisers and investors to achieve their goals. | - |
Jane Nicola Shelton | F | 60 |
The University of Manchester Intellectual Property Ltd.
The University of Manchester Intellectual Property Ltd. Miscellaneous Commercial ServicesCommercial Services The University of Manchester Intellectual Property Ltd. (UMIP) manages intellectual property for the University of Manchester. Formed in 2004, UMIP is a limited company wholly-owned by the University and located in Manchester, UK. They operate independently of the University. The University traces their history back to 1851 and more recently to 2004 when the University formally combined with UMIST (University of Manchester Institute of Science and Technology) to create a single university. UMIP acts as a technology transfer company in the UK. They have access to proof of concept funds to develop very early stage inventions to a phase where they become propositions capable of attracting investments. They also have investment funds to develop young start-up companies, along with the skills and network necessary to draw in the larger sums of external venture capital. UMIP works with researchers, entrepreneurs, business people, professional advisers and investors to achieve their goals. | - |
Rich Ferrie | M | - |
The University of Manchester Intellectual Property Ltd.
The University of Manchester Intellectual Property Ltd. Miscellaneous Commercial ServicesCommercial Services The University of Manchester Intellectual Property Ltd. (UMIP) manages intellectual property for the University of Manchester. Formed in 2004, UMIP is a limited company wholly-owned by the University and located in Manchester, UK. They operate independently of the University. The University traces their history back to 1851 and more recently to 2004 when the University formally combined with UMIST (University of Manchester Institute of Science and Technology) to create a single university. UMIP acts as a technology transfer company in the UK. They have access to proof of concept funds to develop very early stage inventions to a phase where they become propositions capable of attracting investments. They also have investment funds to develop young start-up companies, along with the skills and network necessary to draw in the larger sums of external venture capital. UMIP works with researchers, entrepreneurs, business people, professional advisers and investors to achieve their goals. | - |
Andrew Sherwin | M | - |
Aquarium Software Ltd.
| - |
Neil Andrew Watkins | M | - |
Aero Technics Ltd.
Aero Technics Ltd. Aerospace & DefenseElectronic Technology Aero Technics Ltd. manufactures aircraft parts. The firm offers interior, design, composite materials and kitting services to airlines. The company was founded by Steve Lindsay Cloran in 2002 and is headquartered in Worthing, the United Kingdom. | - |
Roger George Clements | M | - |
Aero Technics Ltd.
Aero Technics Ltd. Aerospace & DefenseElectronic Technology Aero Technics Ltd. manufactures aircraft parts. The firm offers interior, design, composite materials and kitting services to airlines. The company was founded by Steve Lindsay Cloran in 2002 and is headquartered in Worthing, the United Kingdom. | - |
Ed Shropshire | M | - |
Aquarium Software Ltd.
| - |
Malcolm Barratt-Johnson | M | 61 |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 4 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Andrew Justin Radcliffe Porter | M | - |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 12 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 15 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bryan Harvey Bodek
- Persönliches Netzwerk